Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (CAPSTONE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02949011
Recruitment Status : Completed
First Posted : October 31, 2016
Results First Posted : November 6, 2019
Last Update Posted : November 19, 2019
Sponsor:
Information provided by (Responsible Party):
Shionogi Inc. ( Shionogi )

Tracking Information
First Submitted Date  ICMJE October 27, 2016
First Posted Date  ICMJE October 31, 2016
Results First Submitted Date  ICMJE October 18, 2019
Results First Posted Date  ICMJE November 6, 2019
Last Update Posted Date November 19, 2019
Actual Study Start Date  ICMJE January 11, 2017
Actual Primary Completion Date April 12, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 10, 2019)
Time to Improvement of Influenza Symptoms [ Time Frame: From Day 1 pretreatment up to Day 14 ]
Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
  • Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
  • Preexisting symptoms not worse at baseline must have maintained baseline severity
  • New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1).
Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.
Original Primary Outcome Measures  ICMJE
 (submitted: October 27, 2016)
Time to improvement of symptoms [ Time Frame: From Day 1 pretreatment up to Day 14 ]
Time to improvement of symptoms is defined as the time from initiation of study treatment to improvement of influenza symptoms for a duration of at least 21.5 hours (24 hours - 10%).
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 10, 2019)
  • Percentage of Participants With Positive Influenza Virus Titer at Each Time Point [ Time Frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.
  • Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point [ Time Frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9. ]
    Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.
  • Change From Baseline in Virus Titer at Each Time Point [ Time Frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).
  • Change From Baseline in Virus RNA (RT-PCR) at Each Time Point [ Time Frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9 ]
    Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer [ Time Frame: Day 1 to Day 9 ]
    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.
  • Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA [ Time Frame: Day 1 to Day 9 ]
    This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.
  • Time to Cessation of Viral Shedding Determined by Virus Titer [ Time Frame: Day 1 to Day 9 ]
    Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀[TCID₅₀/mL]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.
  • Time to Cessation of Viral Shedding Determined by Virus RNA [ Time Frame: Day 1 to Day 9 ]
    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.
  • Percentage of Participants Whose Symptoms Were Improved at Each Time Point [ Time Frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment ]
    Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
    • Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity
    • Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity
    • New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
  • Time to Alleviation of Symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.
  • Time to Improvement of the Four Systemic Symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
    • Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
    • Preexisting symptoms not worse at baseline must have maintained baseline severity
    • New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
    Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.
  • Time to Improvement of the Three Respiratory Symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours:
    • Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline
    • Preexisting symptoms not worse at baseline must have maintained baseline severity
    • New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).
    Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.
  • Time to Resolution of Fever [ Time Frame: Initiation of study treatment up to Day 14 ]
    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.
  • Percentage of Participants Reporting Normal Temperature at Each Time Point [ Time Frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment ]
    Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.
  • Body Temperature at Each Time Point [ Time Frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment ]
    Participant's self-measured axillary temperature using an electronic thermometer.
  • Time to Improvement of Individual Symptoms [ Time Frame: Initiation of study treatment up to Day 14 ]
    Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours:
    • Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline
    • Preexisting symptoms not worse at baseline must have maintained baseline severity
    • New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours.
    Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.
  • Time to Return to Preinfluenza Health Status [ Time Frame: Baseline to Day 14 ]
    Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health [for someone your age and condition]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.
  • Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection [ Time Frame: Day 2 to Day 22 ]
    The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).
  • Percentage of Participants With Influenza-related Complications [ Time Frame: Day 1 to Day 22 ]
    Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.
  • Percentage of Participants With Adverse Events (AEs) [ Time Frame: From first dose of study drug to Day 22 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: October 27, 2016)
  • Percentage of participants positive for influenza virus titer and viral RNA at each time point [ Time Frame: Days 1, 2, 3, 5 and 9 ]
    Defined as the percentage of patients whose virus titer and ribonucleic acid (RNA) load are not less than the lower limit of quantification among those assessed for virus titer and RNA load. RNA load is measured by reverse transcription polymerase chain reaction (RT-PCR).
  • Change From Baseline in Virus Titer at Each Time Point [ Time Frame: From Day 1 pretreatment to Days 2, 3, 5, and 9 ]
  • Change from Baseline in viral RNA load at each time point [ Time Frame: From Day 1 pretreatment to Days 2, 3, 5, and 9 ]
  • Area under the curve (AUC) adjusted by baseline in virus titer [ Time Frame: Day 1 to Day 9 ]
    Defined as AUC of change from baseline in virus titer. The AUC is calculated using the trapezoidal method.
  • Area under the curve (AUC) adjusted by baseline in viral RNA load [ Time Frame: Day 1 to Day 9 ]
    Defined as AUC of change from baseline in viral RNA load. The AUC is calculated using the trapezoidal method.
  • Time to cessation of viral shedding [ Time Frame: From Day 1 to Day 9 ]
    Defined as the time between the initiation of the study treatment and first time when the virus titer/RT-PCR is less than the lower limit of quantification
  • Percentage of participants whose symptoms have been alleviated at each time point [ Time Frame: Days 2-9, morning and evening, and days 10-14, evenings ]
  • Time to alleviation of symptoms [ Time Frame: Day 1 pretreatment up to Day 14 ]
    Time to alleviation of symptoms is defined as the time between the initiation of the study treatment and the alleviation of influenza symptoms. The alleviation of influenza symptoms is defined as the time when all of 7 influenza symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) have been assessed by the patient.
  • Time to improvement in the 4 systemic symptoms [ Time Frame: Day 1 pretreatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the improvement in the 4 systemic symptoms symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue).
  • Time to improvement in the 3 respiratory symptoms [ Time Frame: Day 1 pretreatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the improvement in the 3 respiratory symptoms (cough, sore throat, and nasal congestion).
  • Time to Resolution of Fever [ Time Frame: Day 1 pretreatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever is defined as the time when the patient's self-measured temperature becomes less than 37ºC.
  • Percentage of Participants Reporting Normal Temperature at Each Time Point [ Time Frame: Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening ]
    Defined as the percentage of patients whose self-measured temperature drops to less than 37ºC after the initiation of the study treatment.
  • Body Temperature at Each Time Point [ Time Frame: Days 1 to 3 at morning, noon, evening and bedtime, Days 4 to 14 morning and evening ]
  • Time to improvement of each influenza symptom [ Time Frame: Day 1 pretreatment up to Day 14 ]
    Defined as the time between the initiation of the study treatment and the alleviation of each influenza symptom.
  • Time to Return to Preinfluenza Health Status [ Time Frame: Day 1 pretreatment up to Day 14 ]
    Patients will be asked to record their preinfluenza health status (for someone your age and your health condition). Return to preinfluenza health status is defined as time from the initiation of the study treatment to time to return to preinfluenza health status.
  • Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection [ Time Frame: Day 2 to Day 22 ]
  • Percentage of Participants With Influenza-related Complications [ Time Frame: Day 1 to Day 22 ]
    Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.
  • Number of participants with adverse events [ Time Frame: Day 1 to Day 22 plus or minus 3 days ]
    The frequency of AEs in patients with influenza after S-033188 , after oseltamivir, and after placebo.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
Official Title  ICMJE A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications
Brief Summary The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Influenza
Intervention  ICMJE
  • Drug: Baloxavir Marboxil
    Tablets taken orally
    Other Names:
    • S-033188
    • Xofluza®
  • Drug: Placebo to Baloxavir Marboxil
    Matching tablets taken orally
  • Drug: Oseltamivir
    Capsules taken orally
    Other Name: Tamiflu®
  • Drug: Placebo to Oseltamivir
    Matching placebo capsules taken orally
Study Arms  ICMJE
  • Experimental: Baloxavir Marboxil
    Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of < 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.
    Interventions:
    • Drug: Baloxavir Marboxil
    • Drug: Placebo to Oseltamivir
  • Active Comparator: Oseltamivir
    Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.
    Interventions:
    • Drug: Placebo to Baloxavir Marboxil
    • Drug: Oseltamivir
  • Placebo Comparator: Placebo
    Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.
    Interventions:
    • Drug: Placebo to Baloxavir Marboxil
    • Drug: Placebo to Oseltamivir
Publications * Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020 Oct;20(10):1204-1214. doi: 10.1016/S1473-3099(20)30004-9. Epub 2020 Jun 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 20, 2018)
2184
Original Estimated Enrollment  ICMJE
 (submitted: October 27, 2016)
2157
Actual Study Completion Date  ICMJE April 20, 2018
Actual Primary Completion Date April 12, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.
  2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.
  3. Patients with a diagnosis of influenza confirmed by all of the following:

    1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken
    2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a negative RIDT may be enrolled if the patient reports contact with a known case of influenza within the prior 7 days and all other inclusion criteria are met.
    3. At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater:

    i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)

  4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

    1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
    2. Time when the patient experiences at least 1 new general or respiratory symptom
  5. If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of study drug
  6. Patients will be considered at high risk* of influenza complications due to the presence of at least 1 of the following inclusion criteria:

    1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
    2. Endocrine disorders (including diabetes mellitus)
    3. Residents of long-term care facilities (eg, nursing homes)
    4. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus [HIV] infection with a CD4 count > 350 cells/mm³ within the last 6 months)
    5. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
    6. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
    7. Adults aged ≥ 65 years
    8. American Indians and Alaskan Natives
    9. Blood disorders (such as sickle cell disease)
    10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
    11. Morbid obesity (body mass index ≥ 40 kg/m²)
    12. Women who are within 2 weeks postpartum and are not breastfeeding

Exclusion Criteria:

  1. Patients with severe influenza virus infection requiring inpatient treatment.
  2. Patients with known allergy to oseltamivir (Tamiflu®).
  3. Patients unable to swallow tablets or capsules.
  4. Patients who have previously received baloxavir marboxil.
  5. Patients weighing ≤ 40 kg.
  6. Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
  7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:

    1. Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
    2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
  8. Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
  9. Patients with liver disease associated with hepatic impairment.
  10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
  11. Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.
  12. Patients with immunosuppression following organ or bone marrow transplants.
  13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.
  14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
  15. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
  16. Patients with known creatinine clearance ≤ 60 mL/min.
  17. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries Australia,   Belgium,   Bulgaria,   Germany,   Hungary,   Japan,   Korea, Republic of,   Latvia,   New Zealand,   Philippines,   Poland,   Romania,   South Africa,   Spain,   Taiwan,   Ukraine,   United Kingdom,   United States
 
Administrative Information
NCT Number  ICMJE NCT02949011
Other Study ID Numbers  ICMJE 1602T0832
2016-002688-32 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Shionogi Inc. ( Shionogi )
Study Sponsor  ICMJE Shionogi
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Shionogi Clinical Trials Administrator Clinical Support Help Line Shionogi
PRS Account Shionogi Inc.
Verification Date November 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP